Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Effectiveness of adjuvant trastuzumab in daily clinical practice
Avtorji:ID Matos, Erika (Avtor)
ID Zakotnik, Branko (Avtor)
ID Grašič-Kuhar, Cvetka (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (549,44 KB)
MD5: 431EAD81FD4682BC6579E9AB034905B0
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice. Patients and methods. An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed. Results. Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021). Conclusions. The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.
Ključne besede:breast cancer, trastuzumab, adjuvant, clinical practice
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.12.2014
Založnik:Association of Radiology and Oncology
Leto izida:2014
Št. strani:str. 403-407, VII
Številčenje:Vol. 48, no. 4
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18662 Novo okno
UDK:618.1-006
ISSN pri članku:1318-2099
DOI:10.2478/raon-2013-0081 Novo okno
COBISS.SI-ID:1778043 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:11.04.2024
Število ogledov:106
Število prenosov:22
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:rak dojke, adjuvantno zdravljenje, klinična praksa, trastuzumab


Nazaj